Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration [1] - The registered product is a cross-matching blood quality control product [1]

Core Viewpoint - The company, Maike Biological (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its new product, cross-matching blood quality control products, which enhances its product portfolio and market competitiveness [1] Group 1 - The newly registered product is intended for quality control in manual and fully automated blood type analysis systems during cross-matching tests [1] - The introduction of this product is expected to positively impact the company's market expansion and future operations [1] - The registration certificate enriches the company's product offerings, contributing to its overall market competitiveness [1]

Core Viewpoint - Anjie's subsidiary, Hangzhou Anji Medical Technology Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration, enhancing its product line in the endoscopy field and improving market competitiveness [1] Group 1: Product Registration - The medical device registration certificate is valid from December 23, 2025, to December 22, 2030 [1] - The registered products include electronic endoscope image processors, upper gastrointestinal electronic endoscopes, and lower gastrointestinal electronic endoscopes [1] Group 2: Product Functionality - These products are designed to process signals from electronic endoscopes, provide illumination, and work in conjunction with image processors to display images for observation, diagnosis, and treatment of the upper and lower gastrointestinal tracts [1] Group 3: Market Impact - The acquisition of the registration certificate enriches the company's product line in the endoscopy sector, which is expected to enhance its overall competitiveness in the market [1]

Core Viewpoint - The company has obtained multiple medical device registration certificates, enhancing its product portfolio in respiratory testing and related technologies [1] Group 1: Medical Device Registrations - The company's wholly-owned subsidiary, American Hengjian, along with Harbin Oriental Gene and Wanzi Jian Bio, has acquired several medical device registration certificates [1] - The registrations include six cytokine detection kits, testosterone and prolactin testing kits, and international certifications for COVID-19 and influenza antigen combined testing kits [1] Group 2: Market Expansion - The acquisition of these certifications will improve the company's product layout in areas such as respiratory testing, time-resolved fluorescence immunochromatography, flow cytometry, and fluorescence immunoassay instruments [1] - This development is expected to facilitate the overall market expansion of related technology platform products [1] Group 3: Sales Performance - Actual sales performance will depend on the competitiveness of the products and the company's market sales capabilities [1] - Currently, it is not possible to predict the impact of these developments on the company's future operating performance [1]

Group 1 - The first extraordinary general meeting of shareholders for Shenzhen Pumen Technology Co., Ltd. was held on December 16, 2025, at the company's headquarters in Shenzhen [2] - All resolutions proposed during the meeting were approved, with no rejected proposals [2] - The meeting was convened by the board of directors and chaired by Chairman Liu Xiancheng, following legal and procedural requirements [2][3] Group 2 - The meeting included the attendance of all 9 current directors and 3 supervisors, along with the board secretary and senior management [3] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association and related rules [4][5] - A proposal for the company to apply for a comprehensive credit limit from banks for the year 2026 was also approved [5] Group 3 - The company recently received two medical device registration certificates for in vitro diagnostic reagents from the Guangdong Provincial Drug Administration [9] - The registered products are composite quality control products that ensure the safety and effectiveness of the company's electrochemical luminescence detection system [9] - As of the announcement date, the company and its subsidiaries have obtained a total of 105 registration certificates for electrochemical luminescence detection reagents, enhancing its product competitiveness in the immunodiagnostic field [9]

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Hunan Yahui Long Biotechnology Co., Ltd., has received medical device registration certificates for two antibody testing kits, enhancing its product line in the field of autoimmune disease detection [1] Group 1 - The registered products are the anti-phosphatidylserine/prothrombin IgM antibody test kit and the anti-phosphatidylserine/prothrombin IgG antibody test kit, both utilizing chemiluminescence methods [1] - The registration numbers for the products are 湘械注准20252400986 and 湘械注准20252400987, with a validity period until December 11, 2030 [1] - The acquisition of these registration certificates will help to further enrich the company's fully automated chemiluminescence product line [1]

Core Viewpoint - The company has received medical device registration certificates for two products, the surgical shadowless lamp and the thoracic and abdominal endoscope, which are expected to enhance its product offerings and competitive edge in the medical device market [1][6]. Group 1: Surgical Shadowless Lamp - Product Name: Surgical Shadowless Lamp [1] - Registration Number: Lu Xie Zhu Zheng 20252010721 [1] - Features: Ultra-thin butterfly design, high color rendering medical LED light source, multiple modes for clinical needs [2] - Applicable Scope: Designed for surgical lighting in medical institutions [1] - Approval Date: November 27, 2025 [1] - Validity Period: Until November 26, 2030 [1] - Market Context: 101 companies in the same industry have obtained similar product registration certificates [1]. Group 2: Thoracic and Abdominal Endoscope - Product Name: Thoracic and Abdominal Endoscope [8] - Registration Number: Lu Xie Zhu Zheng 20252060702 [8] - Features: Dual-mode confocal design, ultra-clear imaging, and durable sapphire lens [5] - Applicable Scope: Used for examination and observation in thoracic and abdominal surgeries [4] - Approval Date: November 19, 2025 [4] - Validity Period: Until November 18, 2030 [4] - Market Context: 13 companies in the same industry have obtained similar product registration certificates [4]. Group 3: Impact on Company Performance - The surgical shadowless lamp meets diverse clinical lighting needs, enriching the company's surgical product line [6] - The thoracic and abdominal endoscope complements the company's medical fluorescence endoscope imaging system and minimally invasive surgical instruments, enhancing its product variety and core competitiveness [6].

Core Viewpoint - Antu Biology (603658.SH) has received medical device registration certificates from the National Medical Products Administration and the Henan Provincial Medical Products Administration, enhancing its product offerings and competitiveness in the market [1] Group 1: Company Developments - The company and its wholly-owned subsidiary, Zhengzhou Sikun Biological Engineering Co., Ltd., along with its secondary subsidiary, Zhengzhou Biaoyuan Biotechnology Co., Ltd., have recently obtained medical device registration certificates [1] - The acquisition of these certificates enriches the company's product menu and meets market demand, serving as an effective supplement to existing testing products [1] Group 2: Market Impact - The new medical device registration is expected to gradually improve the overall competitiveness of the company's products [1] - The short-term impact on the company's operating performance is considered to be minimal [1]

Core Viewpoint - The company Wanfu Bio has received a medical device registration certificate from the National Medical Products Administration for its combined test kit for respiratory syncytial virus (RSV), adenovirus (ADV), and Mycoplasma pneumoniae (MP) antigens, which is expected to positively impact its product offerings and sales growth [1] Group 1 - The product is designed for in vitro qualitative detection of RSV, ADV, and MP antigens in nasopharyngeal swab samples [1] - The approval of the product registration certificate will increase the variety of products available for sale by the company [1] - The company plans to actively promote the sales of the related products, although it is currently unable to predict the impact on future revenue [1]

Core Viewpoint - The announcement indicates that the company has received a medical device registration certificate from the National Medical Products Administration for its blood type identification and irregular antibody screening quality control products, which is expected to enhance its market competitiveness and future operations [1] Group 1: Product Development - The new product registration enriches the company's product portfolio, potentially aiding in market expansion [1] - The actual sales performance of the registered products will depend on future market promotion efforts [1] Group 2: Market Impact - The registration certificate is anticipated to have a positive impact on the company's overall market competitiveness [1] - The future revenue impact of the new product remains unpredictable at this stage [1]